The Prescribing Clinical Network recommends dupilumab as a treatment option for treating moderate to severe atopic dermatitis in line with NICE TA534 (August 2018).
Dupilumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians)
Dupilumab is a payment by results excluded drug and specialists will be required to notify commissioners of initiation and response to treatment using the tick box proformas available on the blueteq system.
